Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Perez-Amill

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancers|October 30, 2020
Natural Killer Cells in Immunotherapy: Are We Nearly There?Mireia Bachiller, Anthony M Battram, Lorena Perez-Amill, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|September 7, 2018
CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer PatientsLorena Perez-Amill, Berta Marzal, Alvaro Urbano-Ispizua, et al.
International Journal of Molecular Sciences|August 30, 2017
Natural Killer Cells: Angels and Devils for ImmunotherapyBeatriz Martín-Antonio, Guillermo Suñe, Lorena Perez-Amill, et al.
Journal for Immunotherapy of Cancer|August 26, 2021
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitnessMireia Bachiller, Lorena Perez-Amill, Anthony Matthew Battram, et al.
Haematologica|January 11, 2020
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myelomaLorena Perez-Amill, Guillermo Suñe, Asier Antoñana-Vildosola, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domainOriol Cardus, Joan Mañé Pujol, Anna de Daniel, et al.
Oncoimmunology|July 13, 2025
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse modelAina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Science Translational Medicine|February 14, 2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoLaura Díez-Alonso, Aïda Falgas, Javier Arroyo-Ródenas, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancers|October 30, 2020
Natural Killer Cells in Immunotherapy: Are We Nearly There?Mireia Bachiller, Anthony M Battram, Lorena Perez-Amill, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|September 7, 2018
CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer PatientsLorena Perez-Amill, Berta Marzal, Alvaro Urbano-Ispizua, et al.
International Journal of Molecular Sciences|August 30, 2017
Natural Killer Cells: Angels and Devils for ImmunotherapyBeatriz Martín-Antonio, Guillermo Suñe, Lorena Perez-Amill, et al.
Journal for Immunotherapy of Cancer|August 26, 2021
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitnessMireia Bachiller, Lorena Perez-Amill, Anthony Matthew Battram, et al.
Haematologica|January 11, 2020
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myelomaLorena Perez-Amill, Guillermo Suñe, Asier Antoñana-Vildosola, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domainOriol Cardus, Joan Mañé Pujol, Anna de Daniel, et al.
Oncoimmunology|July 13, 2025
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse modelAina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Science Translational Medicine|February 14, 2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoLaura Díez-Alonso, Aïda Falgas, Javier Arroyo-Ródenas, et al.
Pageof 1